Iris neoplasm

Summary

Iris neoplasm (MONDO:0021224) is a cancer and 2 clinical trials. A subtype of iris disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	iris neoplasm
Mondo ID	MONDO:0021224
MeSH	D015811
NCIT	C3142
UMLS	C0022079
MedGen	7159
Anatomy (UBERON)	UBERON:0001769
Is cancer (heuristic)	yes

Also known as: iris neoplasm (disease) · iris tumor · iris tumour · neoplasm of iris · neoplasm of the iris · tumor of iris · tumor of the iris · tumour of iris · tumour of the iris

Disease family

This is a subtype of iris disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › uveal disorder › iris disorder › iris neoplasm

Related subtypes (7): pupil disorder, ciliary body disorder, iritis, exfoliation syndrome, aniridia, anterior segment dysgenesis 3, intraoperative floppy iris syndrome

Subtypes (3): iris cancer, ciliary body neoplasm, benign neoplasm of iris

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03809585	Not specified	RECRUITING	Observational Study of Iris Tumors
NCT00406120	Not specified	WITHDRAWN	Validation of a Molecular Prognostic Test for Eye Melanoma